Trials / Completed
CompletedNCT00254267
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors
An Open-label Phase 2 Study of AMG 706 in Japanese Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 706 | AMG 706 125mg, oral, once a day |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2007-02-01
- Completion
- 2012-12-01
- First posted
- 2005-11-16
- Last updated
- 2014-02-27
Source: ClinicalTrials.gov record NCT00254267. Inclusion in this directory is not an endorsement.